{"id":36918,"date":"2026-06-03T19:54:06","date_gmt":"2026-06-03T14:24:06","guid":{"rendered":"https:\/\/atsixty.com\/?p=36918"},"modified":"2026-06-03T19:55:08","modified_gmt":"2026-06-03T14:25:08","slug":"viral-hepatitis","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/","title":{"rendered":"Viral Hepatitis"},"content":{"rendered":"\n\n\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&#038;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&#038;display=swap\" rel=\"stylesheet\">\n<style>\n\/* ============================================================\n   Morning Rounds \u00b7 GIT Quiz 03 \u00b7 Viral Hepatitis\n   Namespace: #git03\n   Palette: deep teal-green (GIT series standard)\n   Template: git02 \u2014 plain diff label, exp + extra Points block\n   ============================================================ *\/\n\n#git03 *,#git03 *::before,#git03 *::after{box-sizing:border-box;margin:0;padding:0}\n\n#git03{\n  --ter:#1A6B5A;\n  --ter-light:#2A8C77;\n  --ter-pale:#EBF6F3;\n  --ter-dark:#125048;\n  --correct:#2D6B47;\n  --correct-bg:#EAF6EF;\n  --correct-border:#3A9960;\n  --wrong:#B83232;\n  --wrong-bg:#FDF0F0;\n  --wrong-border:#E53935;\n  --ink:#1C2E2A;\n  --ink-mid:#3D5A54;\n  --ink-soft:#7A9A94;\n  --line:#D8E8E5;\n  --cream:#F5FAF9;\n  --warm:#FDFFFE;\n\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;color:var(--ink);background:var(--cream);\n  line-height:1.7;padding:0 0 64px;\n}\n\n#git03 .mr-header{background:var(--ter);color:#FDFFFE;padding:34px 24px 28px;text-align:center}\n#git03 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#git03 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#git03 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#git03 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#git03 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#git03 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n\n#git03 .mr-sentinel{height:1px}\n#git03 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(26,107,90,0.10);padding:9px 16px;display:none}\n#git03 .mr-progress.visible{display:block}\n#git03 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#git03 .mr-pips{display:flex;align-items:center;justify-content:center}\n#git03 .mr-pip-wrap{display:flex;align-items:center}\n#git03 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#git03 .mr-pip-line.done{background:var(--ter)}\n#git03 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#git03 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#git03 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n\n#git03 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#git03 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ter);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(26,107,90,0.06)}\n#git03 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#git03 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ter);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#git03 .mr-meta{flex:1}\n#git03 .mr-tag-row{display:flex;align-items:center;justify-content:space-between;margin-bottom:5px}\n#git03 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ter);opacity:0.8}\n#git03 .mr-diff{font-size:0.61rem;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;color:var(--ink-soft)}\n#git03 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#git03 .mr-stem strong{font-weight:600}\n#git03 .mr-stem em{font-style:italic}\n#git03 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n\n#git03 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#git03 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#git03 .mr-opt:hover{border-color:var(--ter);background:var(--ter-pale)}\n#git03 .mr-opt.locked{cursor:default}\n#git03 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#git03 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#git03 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#git03 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#git03 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#git03 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#git03 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#git03 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#git03 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#git03 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#git03 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#git03 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#git03 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n\n#git03 .mr-exp{display:none;border-top:1px solid #b8ddd6;background:linear-gradient(180deg,#e8f5f2 0%,#f2faf8 100%);padding:13px 20px 15px}\n#git03 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--correct);margin-bottom:6px}\n#git03 .mr-exp-text{font-size:0.86rem;color:#1c4a3a;line-height:1.68}\n#git03 .mr-exp-text strong{font-weight:600}\n#git03 .mr-exp-text em{font-style:italic}\n#git03 .mr-exp-extra{margin-top:11px;padding-top:10px;border-top:1px dashed #9ACCC4;font-size:0.84rem;color:#1c4a3a;line-height:1.66}\n#git03 .mr-exp-extra-lbl{font-size:0.59rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--ter);margin-bottom:4px;display:block}\n#git03 .mr-exp-extra strong{font-weight:600}\n#git03 .mr-exp-extra em{font-style:italic}\n\n#git03 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#git03 .mr-btn{background:var(--ter);color:#FDFFFE;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(26,107,90,0.30)}\n#git03 .mr-btn:hover{background:var(--ter-dark)}\n#git03 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ter);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(26,107,90,0.10);overflow:hidden}\n#git03 .mr-score-in{padding:28px 24px;text-align:center}\n#git03 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#git03 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ter) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#git03 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#git03 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#git03 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ter)}\n#git03 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#git03 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#git03 .mr-score-net{font-size:0.9rem;color:var(--ter);font-weight:600;margin-bottom:4px}\n#git03 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#git03 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#git03 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#git03 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#git03 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#git03 .mr-band-s{background:var(--ter-pale);color:var(--ter)}\n#git03 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ter);color:var(--ter);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#git03 .mr-retry:hover{background:var(--ter);color:#FDFFFE}\n\n@media(max-width:480px){\n  #git03 .mr-title{font-size:1.4rem}\n  #git03 .mr-num{font-size:1.7rem}\n  #git03 .mr-stem{font-size:0.9rem}\n  #git03 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"git03\">\n\n  <div class=\"mr-header\">\n    <div class=\"mr-eyebrow\">Morning Rounds &middot; GIT Series<\/div>\n    <div class=\"mr-title\">\n      Viral Hepatitis<br><em>Gastroenterology<\/em>\n    <\/div>\n    <div class=\"mr-subtitle\">Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS<\/div>\n    <div class=\"mr-chips\">\n      <span class=\"mr-chip\">5 Cases<\/span>\n      <span class=\"mr-chip\">+4 \/ &minus;1 scoring<\/span>\n      <span class=\"mr-chip\">Options reshuffled<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-sentinel\" id=\"git03-sentinel\"><\/div>\n\n  <div class=\"mr-progress\" id=\"git03-progress\">\n    <div class=\"mr-prog-inner\">\n      <div class=\"mr-pips\" id=\"git03-pips\"><\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-body\">\n    <div id=\"git03-cases\"><\/div>\n    <div class=\"mr-submit-wrap\">\n      <button class=\"mr-btn\" id=\"git03-submit\">Submit for Debrief<\/button>\n    <\/div>\n    <div class=\"mr-score\" id=\"git03-score\">\n      <div class=\"mr-score-in\">\n        <div class=\"mr-score-ey\">Round Complete<\/div>\n        <div class=\"mr-ring\" id=\"git03-ring\">\n          <div class=\"mr-ring-in\">\n            <span class=\"mr-ring-pct\" id=\"git03-pct\">0%<\/span>\n            <span class=\"mr-ring-sub\">net<\/span>\n          <\/div>\n        <\/div>\n        <div class=\"mr-score-title\">Your Debrief<\/div>\n        <div class=\"mr-score-net\" id=\"git03-net\"><\/div>\n        <div class=\"mr-verdict\" id=\"git03-verdict\"><\/div>\n        <div class=\"mr-bands\">\n          <span class=\"mr-band mr-band-c\" id=\"git03-ct-c\"><\/span>\n          <span class=\"mr-band mr-band-w\" id=\"git03-ct-w\"><\/span>\n          <span class=\"mr-band mr-band-s\" id=\"git03-ct-s\"><\/span>\n        <\/div>\n        <button class=\"mr-retry\" id=\"git03-retry\">&#8635; New Round<\/button>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n\/* ============================================================\n   Morning Rounds \u00b7 GIT Quiz 03 \u00b7 Viral Hepatitis\n   Namespace : git03\n   TOTAL     : 5 questions  |  MAX : 20  |  +4 \/ \u22121\n   Shuffle   : Fisher-Yates on options each build()\n   Correct   : matched by answer TEXT\n   Debrief   : q.exp = main text; q.extra = Extra Points para\n   ============================================================ *\/\n(function () {\n  'use strict';\n\n  var NS    = 'git03';\n  var TOTAL = 5;\n  var MAX   = 20;\n  var LTRS  = ['A','B','C','D'];\n\n  \/* ================================================================\n     QUESTION BANK \u2014 Viral Hepatitis\n     Topics: Hep A & E (feco-oral, epidemic), Hep B serology,\n             Hep B chronic \/ HBeAg \/ replication markers,\n             Hep C (diagnosis, cure, DAAs),\n             Fulminant Hepatic Failure (causes, management)\n\n     Q1  HEPATITIS A & E \u2014 FECO-ORAL, EPIDEMIC JAUNDICE (Easy)\n         Both RNA viruses; feco-oral transmission.\n         Hep A (HAV): picornavirus; self-limiting; no chronicity;\n           vaccine available; commoner in children.\n         Hep E (HEV): calicivirus\/hepevirus; self-limiting in\n           immunocompetent; NO chronicity in immunocompetent;\n           BUT chronic HEV in immunosuppressed (transplant pts).\n           HIGH MORTALITY in pregnancy \u2014 up to 20\u201325%\n           especially in 3rd trimester \u2192 FHF.\n           Responsible for epidemic jaundice in India\n           (contaminated water supply).\n           No licensed vaccine in India.\n         Both: anti-HAV IgM \/ anti-HEV IgM = acute infection.\n         Management: supportive; avoid alcohol; no specific Rx.\n         Answer: HEV has high mortality in pregnancy (~20-25%);\n                 epidemic jaundice India = HEV (waterborne);\n                 no chronicity in immunocompetent.\n\n     Q2  HEPATITIS B \u2014 SEROLOGICAL MARKERS (Medium)\n         HBsAg: surface antigen; first marker to appear (4\u201312 wk);\n           positive = infected (acute or chronic).\n         Anti-HBs: protective antibody; appears after HBsAg\n           clears; indicates recovery OR vaccination.\n           ONLY anti-HBs positive (no anti-HBc) = vaccination.\n         HBeAg: envelope antigen; marker of active replication\n           and HIGH infectivity; correlates with HBV DNA.\n         Anti-HBe: seroconversion from HBeAg; indicates \u2193\n           replication; better prognosis (in wild-type HBV).\n         Anti-HBc IgM: acute hepatitis B (window period marker).\n         Anti-HBc IgG: past infection (lifelong) OR chronic.\n         Window period: HBsAg cleared, anti-HBs not yet risen;\n           ONLY anti-HBc IgM positive \u2014 diagnoses window.\n         Chronic HBV: HBsAg positive > 6 months.\n         HBsAg + Anti-HBs simultaneously possible in:\n           superinfection, mutant virus, or immunosuppression.\n         Answer: Window period = anti-HBc IgM only positive;\n                 anti-HBs alone = vaccination; HBeAg = high\n                 infectivity \/ active replication.\n\n     Q3  HEPATITIS B \u2014 PRECORE MUTANT & REACTIVATION (Hard)\n         Precore mutant (HBeAg-negative chronic HBV):\n           Mutation in precore region \u2192 cannot produce HBeAg.\n           Patient has ACTIVE replication (high HBV DNA)\n           but HBeAg NEGATIVE and anti-HBe POSITIVE.\n           Anti-HBe seroconversion does NOT mean low infectivity\n           in this case \u2014 common exam trap.\n           Common in Mediterranean, Middle East, India.\n         HBV reactivation:\n           Occurs in anti-HBc positive patients on\n           immunosuppression (rituximab, steroids, chemo).\n           Prophylactic antiviral (entecavir\/tenofovir)\n           must be given before immunosuppression.\n         Treatment of chronic HBV:\n           Pegylated IFN-\u03b1: finite duration (48 wks);\n             higher HBsAg loss rate; not for cirrhosis\/decompensated.\n           Tenofovir \/ Entecavir: oral; indefinite; low resistance;\n             preferred for cirrhosis, HBeAg+, high HBV DNA.\n         Answer: Precore mutant \u2014 HBeAg \u2212ve but high HBV DNA,\n                 anti-HBe +ve does NOT imply low infectivity;\n                 tenofovir\/entecavir = preferred oral antivirals.\n\n     Q4  HEPATITIS C \u2014 DIAGNOSIS & CURE WITH DAAs (Medium)\n         HCV: RNA flavivirus; 6 genotypes (1\u20136); genotype 1\n           commonest globally; genotype 3 commonest in India.\n         Transmission: parenteral (IVDU, needle-stick, unsafe\n           transfusion); sexual (low risk); vertical (low risk).\n           NO feco-oral transmission.\n         Screening: anti-HCV antibody (ELISA) \u2014 detects exposure,\n           NOT active infection; window period ~8\u201312 weeks.\n         Confirmation of active infection: HCV RNA (PCR) \u2014 gold\n           standard; positive from 1\u20132 weeks after exposure.\n         Chronicity: 75\u201385% progress to chronic hepatitis C\n           (unlike HAV\/HEV which never cause chronicity).\n         Treatment: Direct-Acting Antivirals (DAAs):\n           Sofosbuvir-based regimens (pan-genotypic):\n             Sofosbuvir + Velpatasvir \u00d7 12 wks \u2014 SVR >95%.\n           SVR (sustained virological response) = HCV RNA\n           undetectable 12 wks post-treatment = CURE.\n           India: generic DAAs widely available; HCV is curable.\n         Answer: Anti-HCV = exposure\/screening; HCV RNA = active\n                 infection; DAAs achieve cure (SVR >95%);\n                 genotype 3 commonest in India.\n\n     Q5  FULMINANT HEPATIC FAILURE \u2014 CAUSES & MANAGEMENT (Hard)\n         FHF (Acute Liver Failure): hepatic encephalopathy within\n           8 weeks of onset of jaundice in a patient with no\n           prior liver disease.\n         Causes in India:\n           #1: Viral hepatitis \u2014 HEV (esp. pregnancy), HAV,\n               HBV (acute), HBV + HDV co\/superinfection.\n           Others: paracetamol overdose (#1 in West),\n               Wilson's disease, Budd-Chiari, drugs (INH,\n               halothane, valproate), mushroom poisoning\n               (Amanita phalloides).\n         HDV (Hep D): defective RNA virus; REQUIRES HBsAg\n           (needs HBV envelope to infect).\n           Co-infection (HBV+HDV simultaneously): usually\n             self-limiting, rarely FHF.\n           Superinfection (HDV in chronic HBV carrier):\n             HIGH risk of FHF and rapid cirrhosis.\n         Management: ICU; N-acetylcysteine (paracetamol OD);\n           lactulose (encephalopathy); avoid sedatives\/opioids;\n           treat coagulopathy; liver transplantation = definitive.\n         King's College Criteria: guide transplant listing.\n         Answer: India FHF #1 = viral (HEV in pregnancy);\n                 HDV superinfection > co-infection for FHF risk;\n                 paracetamol OD = N-acetylcysteine.\n     ================================================================ *\/\n\n  var QS = [\n\n    \/* ---- Q1 : Hepatitis A & E ---- *\/\n    {\n      id:      1,\n      diff:    'Easy',\n      tag:     'Viral Hepatitis &mdash; Hep A &amp; E',\n      stem:    'During a <strong>monsoon season outbreak of jaundice<\/strong> in a village in Jharkhand, a <strong>28-year-old woman in her third trimester of pregnancy<\/strong> develops acute jaundice with rapid onset of confusion and coagulopathy. Several non-pregnant villagers have milder jaundice resolving spontaneously. The water supply was recently found to be contaminated. Which virus is most responsible for the severe outcome in the pregnant woman, and what is its key epidemiological feature in India?',\n      correct: 'Hepatitis E virus (HEV); transmitted feco-orally via contaminated water; causes epidemic jaundice in India; carries up to 20\u201325% mortality in the third trimester of pregnancy due to fulminant hepatic failure',\n      opts: [\n        'Hepatitis E virus (HEV); transmitted feco-orally via contaminated water; causes epidemic jaundice in India; carries up to 20\u201325% mortality in the third trimester of pregnancy due to fulminant hepatic failure',\n        'Hepatitis A virus (HAV); transmitted feco-orally; causes fulminant hepatic failure specifically in pregnant women in the third trimester; no vaccine is available',\n        'Hepatitis B virus (HBV); transmitted parenterally; the waterborne outbreak pattern confirms vertical transmission from mother to child during the monsoon season',\n        'Hepatitis C virus (HCV); transmitted via contaminated water during floods; causes epidemic jaundice with high mortality in pregnancy due to its high chronicity rate'\n      ],\n      exp: '<strong>Hepatitis E virus (HEV)<\/strong> is the most important cause of <strong>epidemic (waterborne) jaundice in India<\/strong>, transmitted feco-orally through contaminated drinking water \u2014 exactly the scenario described. In immunocompetent non-pregnant individuals, HEV is self-limiting with no chronicity. However, in <strong>pregnancy \u2014 particularly the third trimester<\/strong> \u2014 HEV causes fulminant hepatic failure with a mortality rate of <strong>20\u201325%<\/strong>, one of the highest of any viral hepatitis. The mechanism is not fully understood but involves hormonal modulation of immune response and altered viral replication. <strong>HAV<\/strong> is also feco-oral and causes epidemic jaundice, but it does <em>not<\/em> carry the same high maternal mortality. A licensed HAV vaccine exists; there is no licensed HEV vaccine in India. <strong>Diagnosis:<\/strong> anti-HEV IgM (acute) \/ anti-HEV IgG (past infection or convalescent).',\n      extra: '<strong>Chronic HEV<\/strong> \u2014 an important and frequently tested exception: HEV causes chronic infection (persisting &gt;3 months) in <em>immunosuppressed<\/em> patients, especially solid organ transplant recipients on tacrolimus or mycophenolate. This can progress to cirrhosis and is treated with ribavirin dose reduction of immunosuppression. This exception is a reliable NEET-PG question stem. <strong>HDV reminder:<\/strong> Hepatitis D is also RNA-based but is not waterborne \u2014 it is a defective virus requiring HBsAg and is covered in Q5. <strong>CMS relevance:<\/strong> A district medical officer must recognise HEV as the primary culprit in any waterborne jaundice outbreak and prioritise pregnant women for close monitoring and early referral.'\n    },\n\n    \/* ---- Q2 : Hep B Serology ---- *\/\n    {\n      id:      2,\n      diff:    'Medium',\n      tag:     'Viral Hepatitis &mdash; Hep B Serology',\n      stem:    'A <strong>30-year-old healthcare worker<\/strong> undergoes pre-employment hepatitis B serology. Results: <strong>HBsAg negative, anti-HBs positive, anti-HBc negative<\/strong>. A colleague tested the same week shows: <strong>HBsAg negative, anti-HBs negative, anti-HBc IgM positive<\/strong>. A third staff member shows: <strong>HBsAg positive, HBeAg positive, anti-HBc IgG positive, HBV DNA very high<\/strong>. Which interpretation correctly identifies the serological status of all three individuals?',\n      correct: 'First: vaccinated (anti-HBs alone, no anti-HBc \u2014 no natural infection); Second: window period of acute HBV (anti-HBc IgM positive, HBsAg already cleared, anti-HBs not yet risen); Third: chronic HBV with active replication and high infectivity (HBeAg positive)',\n      opts: [\n        'First: vaccinated (anti-HBs alone, no anti-HBc \u2014 no natural infection); Second: window period of acute HBV (anti-HBc IgM positive, HBsAg already cleared, anti-HBs not yet risen); Third: chronic HBV with active replication and high infectivity (HBeAg positive)',\n        'First: recovered from past HBV infection (anti-HBs and anti-HBc both expected after natural infection); Second: early acute HBV (HBsAg not yet detectable, anti-HBc IgM confirms first week of infection); Third: acute HBV with high viral load (HBsAg positive for less than 6 months)',\n        'First: vaccinated; Second: false-positive anti-HBc IgM due to rheumatoid factor \u2014 no further action needed; Third: acute HBV with HBeAg confirming high replication, requires immediate isolation',\n        'First: susceptible \u2014 anti-HBs without anti-HBc indicates waning immunity from natural infection decades ago; Second: resolved acute HBV; Third: HBV carrier state with low infectivity despite positive HBeAg'\n      ],\n      exp: '<strong>HBV serology interpretation<\/strong> is the single most tested topic in hepatitis for both NEET-PG and CMS.<br><br><strong>First worker \u2014 Vaccinated:<\/strong> Anti-HBs positive alone (no anti-HBc) = vaccine response. After natural infection, both anti-HBs and anti-HBc develop. Vaccination generates anti-HBs only \u2014 no anti-HBc, because the core antigen is never expressed.<br><br><strong>Second worker \u2014 Window period:<\/strong> HBsAg has cleared but anti-HBs has not yet risen \u2014 the serological gap. The only positive marker is <strong>anti-HBc IgM<\/strong>, which is the diagnostic marker of the window period (and of acute HBV in general). This is the most tested scenario in HBV serology.<br><br><strong>Third worker \u2014 Chronic active HBV:<\/strong> HBsAg positive for (implied) &gt;6 months = chronic. <strong>HBeAg positive<\/strong> = active viral replication, high HBV DNA, and <strong>high infectivity<\/strong>. Anti-HBc IgG = past exposure \/ chronic infection marker (lifelong).',\n      extra: '<strong>Quick reference table \u2014 key HBV states:<\/strong><br>Acute HBV: HBsAg +, anti-HBc IgM +, HBeAg +<br>Window period: HBsAg \u2212, anti-HBs \u2212, anti-HBc IgM + <em>(only positive marker)<\/em><br>Recovered: HBsAg \u2212, anti-HBs +, anti-HBc IgG +<br>Vaccinated: HBsAg \u2212, anti-HBs +, anti-HBc \u2212 <em>(no core antibody)<\/em><br>Chronic active: HBsAg +, HBeAg +, anti-HBc IgG +, high HBV DNA<br>Chronic inactive carrier: HBsAg +, anti-HBe +, low\/undetectable HBV DNA<br><br><strong>Infectivity order:<\/strong> HBeAg-positive chronic &gt; acute HBV &gt; HBeAg-negative chronic carrier. <strong>Vertical transmission<\/strong> from HBeAg-positive mothers is the dominant route of HBV acquisition in India \u2014 90% of perinatally infected infants develop chronic HBV.'\n    },\n\n    \/* ---- Q3 : Precore Mutant & Reactivation ---- *\/\n    {\n      id:      3,\n      diff:    'Hard',\n      tag:     'Viral Hepatitis &mdash; Hep B Precore Mutant',\n      stem:    'A <strong>45-year-old man<\/strong> known to have chronic hepatitis B is being evaluated for treatment. His serology shows: <strong>HBsAg positive, HBeAg negative, anti-HBe positive<\/strong>. However, his <strong>HBV DNA is 2 \u00d7 10<sup>6<\/sup> IU\/mL<\/strong> and his ALT is persistently elevated. His physician explains that anti-HBe positivity does not indicate low infectivity in this case. The mutation responsible and the preferred first-line oral antiviral for chronic HBV with this profile are:',\n      correct: 'Precore mutation (G1896A) prevents HBeAg synthesis despite active viral replication; HBV DNA and ALT are the true markers of disease activity; tenofovir disoproxil fumarate or entecavir \u2014 high barrier to resistance, preferred over lamivudine',\n      opts: [\n        'Precore mutation (G1896A) prevents HBeAg synthesis despite active viral replication; HBV DNA and ALT are the true markers of disease activity; tenofovir disoproxil fumarate or entecavir \u2014 high barrier to resistance, preferred over lamivudine',\n        'Precore mutation causes deletion of HBsAg expression, leading to false-negative surface antigen in a highly replicating patient; adefovir is the preferred agent as it specifically targets precore mutants',\n        'Core promoter mutation increases HBeAg production paradoxically; the high HBV DNA reflects immune-tolerant phase requiring no treatment; pegylated interferon is the only effective therapy',\n        'Immune escape mutation in the surface gene causes anti-HBs and HBsAg to coexist; lamivudine is first-line as it has the highest barrier to resistance among nucleoside analogues for this variant'\n      ],\n      exp: '<strong>Precore mutant HBV<\/strong> arises from a point mutation (G1896A) in the precore region of the HBV genome, creating a premature stop codon that <strong>prevents synthesis of HBeAg<\/strong>. The patient therefore tests HBeAg-negative and anti-HBe-positive, which in wild-type HBV would suggest low replication. However, in precore mutant infection, <strong>HBV DNA remains high and liver damage continues<\/strong> \u2014 anti-HBe positivity is completely misleading. <strong>True markers of disease activity in this setting:<\/strong> HBV DNA level and ALT. This variant is common in the Mediterranean, Middle East, and India. <strong>Treatment:<\/strong> <strong>Tenofovir disoproxil fumarate (TDF)<\/strong> or <strong>entecavir<\/strong> \u2014 both have a high genetic barrier to resistance and are preferred over lamivudine (high resistance rate with monotherapy) or adefovir (nephrotoxic, weaker). Tenofovir alafenamide (TAF) is preferred over TDF in patients with renal impairment or osteoporosis.',\n      extra: '<strong>HBV reactivation<\/strong> is a critical safety issue for CMS practitioners: patients who are anti-HBc positive (past or occult HBV) and receive immunosuppressive therapy \u2014 particularly <strong>rituximab<\/strong> (highest risk), high-dose corticosteroids, or chemotherapy \u2014 can develop life-threatening HBV reactivation. <strong>All patients being started on immunosuppression must be screened<\/strong> for HBsAg and anti-HBc. Those at risk should receive prophylactic <strong>entecavir or tenofovir<\/strong> starting 1\u20132 weeks before immunosuppression and continuing for 6\u201312 months after. This is a patient-safety point with direct CMS exam relevance \u2014 a general physician initiating steroids for any chronic illness needs to know this.'\n    },\n\n    \/* ---- Q4 : Hepatitis C ---- *\/\n    {\n      id:      4,\n      diff:    'Medium',\n      tag:     'Viral Hepatitis &mdash; Hepatitis C',\n      stem:    'A <strong>38-year-old man<\/strong> who is an injecting drug user is found to have <strong>anti-HCV antibody positive<\/strong> on screening. His <strong>HCV RNA (PCR) is positive<\/strong> at 1.2 \u00d7 10<sup>6<\/sup> IU\/mL, and genotyping reveals <strong>genotype 3<\/strong>. His liver biopsy shows moderate fibrosis (F2). He asks whether he can be cured. Which statement correctly describes the distinction between the screening test and the confirmatory test, the predominant genotype in India, and the achievable treatment outcome?',\n      correct: 'Anti-HCV antibody confirms exposure but not active infection; HCV RNA (PCR) confirms active viraemia; genotype 3 is the most common in India; sofosbuvir-based direct-acting antivirals achieve sustained virological response (SVR) in >95% \u2014 equivalent to cure',\n      opts: [\n        'Anti-HCV antibody confirms exposure but not active infection; HCV RNA (PCR) confirms active viraemia; genotype 3 is the most common in India; sofosbuvir-based direct-acting antivirals achieve sustained virological response (SVR) in >95% \u2014 equivalent to cure',\n        'Anti-HCV IgM confirms acute active infection and is used to distinguish acute from chronic HCV; HCV RNA is used only to monitor treatment response, not for diagnosis; genotype 1 is most common in India; pegylated interferon + ribavirin remains the standard of care',\n        'Anti-HCV antibody confirms both exposure and active infection; HCV RNA is needed only if genotyping is required; genotype 2 predominates in India; ledipasvir-sofosbuvir is genotype-specific and cannot be used for genotype 3',\n        'HCV RNA becomes positive only after 12 weeks of infection (later than anti-HCV antibody); genotype 4 predominates in India; DAAs achieve SVR in only 60\u201370% of genotype 3, making interferon still necessary'\n      ],\n      exp: '<strong>HCV diagnosis \u2014 two-step approach:<\/strong><br><strong>Step 1 \u2014 Screening:<\/strong> Anti-HCV antibody (ELISA\/rapid test). Detects <em>exposure<\/em>, not active infection. Window period: 8\u201312 weeks. A positive result means the patient has been exposed \u2014 it does not distinguish active infection from resolved infection (antibodies persist lifelong after clearance).<br><strong>Step 2 \u2014 Confirmation:<\/strong> <strong>HCV RNA (PCR)<\/strong> \u2014 detects active viraemia, becomes positive within 1\u20132 weeks of infection (earlier than antibody). A positive HCV RNA = active infection requiring treatment.<br><br><strong>Genotypes in India:<\/strong> Genotype 3 is the most prevalent (~60\u201370% of cases), followed by genotype 1. Genotype 3 is associated with more rapid fibrosis progression and higher risk of hepatocellular carcinoma compared to other genotypes.<br><br><strong>Treatment:<\/strong> Pan-genotypic DAA regimens \u2014 <strong>Sofosbuvir + Velpatasvir<\/strong> \u00d7 12 weeks achieves SVR &gt;95% across all genotypes including genotype 3. SVR = HCV RNA undetectable 12 weeks after completing treatment = <strong>virological cure<\/strong>. Generic DAAs are available in India at low cost.',\n      extra: '<strong>HCV does NOT cause feco-oral transmission<\/strong> \u2014 a common exam distractor. Transmission is parenteral (IVDU is the dominant route globally), low-risk sexual, and low-risk vertical. There is <strong>no vaccine<\/strong> for HCV. <strong>Post-SVR:<\/strong> Cured patients remain anti-HCV positive for life (antibody does not disappear) \u2014 this is a clinical trap; do not retest antibody to assess cure; use HCV RNA at 12 weeks post-treatment. Patients with advanced fibrosis (F3\u2013F4) still require surveillance for hepatocellular carcinoma (6-monthly ultrasound + AFP) even after achieving SVR, as cirrhosis-related HCC risk persists. This distinction \u2014 cured of virus but still at HCC risk \u2014 is a high-yield exam point.'\n    },\n\n    \/* ---- Q5 : Fulminant Hepatic Failure ---- *\/\n    {\n      id:      5,\n      diff:    'Hard',\n      tag:     'Viral Hepatitis &mdash; Fulminant Hepatic Failure',\n      stem:    'A <strong>chronic hepatitis B carrier<\/strong> is admitted with <strong>rapidly worsening jaundice, coagulopathy (INR 4.2), and grade III hepatic encephalopathy<\/strong> developing over 10 days. He received a <strong>blood transfusion<\/strong> six weeks ago at a private facility. His serology now shows: HBsAg positive, <strong>anti-HDV IgM positive<\/strong>, HBV DNA low. His prior records confirm he was a stable HBsAg carrier with normal LFTs six months ago. The mechanism of his deterioration, and how this differs from HBV\u2013HDV co-infection, are:',\n      correct: 'HDV superinfection of a chronic HBV carrier: HDV acquires HBsAg as its envelope and replicates aggressively, causing high risk of fulminant hepatic failure and accelerated cirrhosis; co-infection (simultaneous HBV+HDV in a naive host) is usually self-limiting with lower FHF risk',\n      opts: [\n        'HDV superinfection of a chronic HBV carrier: HDV acquires HBsAg as its envelope and replicates aggressively, causing high risk of fulminant hepatic failure and accelerated cirrhosis; co-infection (simultaneous HBV+HDV in a naive host) is usually self-limiting with lower FHF risk',\n        'HBV co-infection with HDV in a previously uninfected host: both viruses establish simultaneously, leading to the most severe form of acute hepatitis; superinfection in a carrier is paradoxically mild as partial immunity exists',\n        'HDV infects independently of HBV in immunocompromised patients; the low HBV DNA confirms that HDV has replaced HBV as the dominant virus; interferon-alpha is contraindicated in this setting',\n        'HDV superinfection causes the immune system to clear HBsAg, leading to spontaneous HBV resolution; the rising INR reflects immune reconstitution hepatitis rather than liver failure'\n      ],\n      exp: '<strong>Hepatitis D virus (HDV)<\/strong> is a defective RNA virus \u2014 it cannot complete its life cycle or form new virions without <strong>HBsAg<\/strong> as its outer envelope. Therefore HDV only infects: (1) simultaneously with HBV (<strong>co-infection<\/strong>) in a previously uninfected person, or (2) a person who is already a chronic HBV carrier (<strong>superinfection<\/strong>).<br><br><strong>Co-infection (HBV + HDV together):<\/strong> usually self-limiting acute hepatitis; both viruses are cleared together in most cases; FHF risk is present but relatively lower.<br><br><strong>Superinfection (HDV acquiring HBsAg from existing chronic HBV):<\/strong> far more dangerous \u2014 HDV replicates aggressively using the abundant HBsAg available from chronic HBV infection. Leads to a <strong>high risk of fulminant hepatic failure<\/strong> and, in survivors, rapidly progressive cirrhosis. This patient had a stable chronic HBV carrier state that decompensated acutely after what was likely a parenteral HDV exposure (contaminated transfusion).<br><br><strong>The paradox:<\/strong> HBV DNA is often suppressed\/low during HDV superinfection \u2014 HDV outcompetes HBV for replication. A stable HBV carrier suddenly deteriorating = always consider HDV superinfection.',\n      extra: '<strong>Fulminant Hepatic Failure (FHF) in India \u2014 causes by frequency:<\/strong> Viral hepatitis dominates (HEV especially in pregnant women, HAV, HBV, HDV superinfection). In the West, <strong>paracetamol (acetaminophen) overdose<\/strong> is the leading cause \u2014 treated with <strong>N-acetylcysteine (NAC)<\/strong>, most effective within 8\u201310 hours of overdose but beneficial even late. Other causes: Wilson\\'s disease (FHF in young patient + haemolytic anaemia + Kayser-Fleischer rings), Budd-Chiari syndrome, drugs (isoniazid, halothane, valproate), <em>Amanita phalloides<\/em> mushroom poisoning. <strong>King\\'s College Criteria<\/strong> guide liver transplant listing \u2014 for paracetamol OD: pH &lt;7.3 after resuscitation, or the triad of INR &gt;6.5 + creatinine &gt;300 \u00b5mol\/L + grade III\u2013IV encephalopathy. Liver transplantation remains the only definitive treatment for FHF not responding to supportive care.'\n    }\n\n  ];\n  \/* ================================================================\n     END OF CONTENT \u2014 engine logic below, do not edit\n     ================================================================ *\/\n\n  var answers  = {};\n  var answered = 0;\n  var shuffled = {};\n  var done     = false;\n\n  function byId(id) { return document.getElementById(id); }\n  function gid(sfx) { return byId(NS + '-' + sfx); }\n\n  function shuffleArr(arr) {\n    var a = arr.slice(), i, j, t;\n    for (i = a.length - 1; i > 0; i--) {\n      j = Math.floor(Math.random() * (i + 1));\n      t = a[i]; a[i] = a[j]; a[j] = t;\n    }\n    return a;\n  }\n\n  function countVal(val) {\n    var k, n = 0;\n    for (k in answers) {\n      if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n    }\n    return n;\n  }\n\n  function buildPips() {\n    var cont = gid('pips'), i, q, wl, wp, line, pip;\n    if (!cont) return;\n    cont.innerHTML = '';\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      if (i > 0) {\n        wl = document.createElement('div'); wl.className = 'mr-pip-wrap';\n        line = document.createElement('div'); line.className = 'mr-pip-line';\n        line.id = NS + '-pl' + q.id;\n        wl.appendChild(line); cont.appendChild(wl);\n      }\n      wp  = document.createElement('div'); wp.className = 'mr-pip-wrap';\n      pip = document.createElement('div'); pip.className = 'mr-pip';\n      pip.id = NS + '-pip' + q.id;\n      pip.textContent = String(q.id);\n      wp.appendChild(pip); cont.appendChild(wp);\n    }\n  }\n\n  function build() {\n    var cont, i, q, opts, card, top, nd, meta, tagRow, tg, dl,\n        st, rule, od, ed, lb, tx, ep, epl, ept, j, oe, ls, ts;\n    cont = gid('cases');\n    if (!cont) return;\n    cont.innerHTML = '';\n    answers = {}; answered = 0; shuffled = {}; done = false;\n    if (gid('score')) gid('score').style.display = 'none';\n    buildPips();\n    for (i = 0; i < QS.length; i++) {\n      q    = QS[i];\n      opts = shuffleArr(q.opts);\n      shuffled[q.id] = opts;\n\n      card = document.createElement('div'); card.className = 'mr-case';\n      top  = document.createElement('div'); top.className  = 'mr-case-top';\n      nd   = document.createElement('div'); nd.className   = 'mr-num';\n      nd.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n      meta = document.createElement('div'); meta.className = 'mr-meta';\n\n      tagRow = document.createElement('div'); tagRow.className = 'mr-tag-row';\n      tg = document.createElement('div'); tg.className = 'mr-tag'; tg.innerHTML = q.tag;\n      dl = document.createElement('div'); dl.className = 'mr-diff'; dl.textContent = q.diff;\n      tagRow.appendChild(tg); tagRow.appendChild(dl);\n\n      st = document.createElement('div'); st.className = 'mr-stem'; st.innerHTML = q.stem;\n      meta.appendChild(tagRow); meta.appendChild(st);\n      top.appendChild(nd); top.appendChild(meta);\n      card.appendChild(top);\n\n      rule = document.createElement('div'); rule.className = 'mr-rule';\n      card.appendChild(rule);\n\n      od = document.createElement('div'); od.className = 'mr-opts';\n      for (j = 0; j < opts.length; j++) {\n        oe = document.createElement('div'); oe.className = 'mr-opt';\n        oe.id = NS + '-o' + q.id + '-' + j;\n        oe.setAttribute('role', 'button'); oe.setAttribute('tabindex', '0');\n        ls = document.createElement('span'); ls.className = 'mr-ltr'; ls.textContent = LTRS[j];\n        ts = document.createElement('span'); ts.className = 'mr-opt-text'; ts.innerHTML = opts[j];\n        oe.appendChild(ls); oe.appendChild(ts); od.appendChild(oe);\n        (function (qid, oi) {\n          oe.addEventListener('click', function () { pick(qid, oi); });\n        }(q.id, j));\n      }\n      card.appendChild(od);\n\n      ed  = document.createElement('div'); ed.className = 'mr-exp'; ed.id = NS + '-exp' + q.id;\n      lb  = document.createElement('div'); lb.className = 'mr-exp-lbl'; lb.textContent = 'Debrief';\n      tx  = document.createElement('div'); tx.className = 'mr-exp-text'; tx.innerHTML = q.exp;\n      ed.appendChild(lb); ed.appendChild(tx);\n\n      if (q.extra) {\n        ep  = document.createElement('div'); ep.className = 'mr-exp-extra';\n        epl = document.createElement('span'); epl.className = 'mr-exp-extra-lbl'; epl.textContent = 'Extra Points';\n        ept = document.createElement('div'); ept.innerHTML = q.extra;\n        ep.appendChild(epl); ep.appendChild(ept);\n        ed.appendChild(ep);\n      }\n\n      card.appendChild(ed);\n      cont.appendChild(card);\n    }\n  }\n\n  function pick(qid, oi) {\n    var q, opts, i, el, ok;\n    if (answers[qid] !== undefined || done) return;\n    q = null;\n    for (i = 0; i < QS.length; i++) { if (QS[i].id === qid) { q = QS[i]; break; } }\n    if (!q) return;\n    opts = shuffled[qid];\n    ok   = (opts[oi] === q.correct);\n    answers[qid] = ok ? 'c' : 'w';\n    answered++;\n    for (i = 0; i < opts.length; i++) {\n      el = byId(NS + '-o' + qid + '-' + i);\n      if (!el) continue;\n      el.className = opts[i] === q.correct ? 'mr-opt correct locked'\n                   : i === oi              ? 'mr-opt wrong locked'\n                                           : 'mr-opt dimmed locked';\n    }\n    var ex = byId(NS + '-exp' + qid); if (ex) ex.style.display = 'block';\n    var pp = byId(NS + '-pip' + qid); if (pp) pp.className = 'mr-pip ' + (ok ? 'correct' : 'wrong');\n    if (qid > 1) { var pl = gid('pl' + qid); if (pl) pl.className = 'mr-pip-line done'; }\n  }\n\n  function showScore() {\n    var c, w, s, net, pct, disp, vlist, vi, sc;\n    if (done) return;\n    done = true;\n    c   = countVal('c'); w = countVal('w'); s = TOTAL - answered;\n    net  = c * 4 - w;\n    pct  = Math.max(0, Math.round((net \/ MAX) * 100));\n    disp = Math.min(100, Math.max(0, pct));\n    var rg = gid('ring');\n    if (rg) rg.style.background = 'conic-gradient(#1A6B5A ' + disp + '%, #D8E8E5 0%)';\n    var pe = gid('pct'); if (pe) pe.textContent = pct + '%';\n    var ne = gid('net'); if (ne) ne.textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n    vlist = [\n      [5, 'Flawless. Viral hepatitis holds no traps for you.'],\n      [4, 'Strong round \\u2014 one marker or mechanism worth a second look.'],\n      [3, 'Solid base \\u2014 the serology patterns reward one more focused read.'],\n      [2, 'Halfway there \\u2014 HBV serology and HDV superinfection are the places to focus.'],\n      [0, 'Viral hepatitis is high yield and very learnable. The debrief panels have everything.']\n    ];\n    var ve = gid('verdict');\n    if (ve) {\n      ve.textContent = vlist[4][1];\n      for (vi = 0; vi < vlist.length; vi++) {\n        if (c >= vlist[vi][0]) { ve.textContent = vlist[vi][1]; break; }\n      }\n    }\n    var cc = gid('ct-c'); if (cc) cc.textContent = '\\u2705 ' + c + ' Correct';\n    var cw = gid('ct-w'); if (cw) cw.textContent = '\\u274C ' + w + ' Wrong';\n    var cs = gid('ct-s'); if (cs) cs.textContent = '\\u23ED ' + s + ' Skipped';\n    sc = gid('score');\n    if (sc) { sc.style.display = 'block'; sc.scrollIntoView({ behavior: 'smooth', block: 'center' }); }\n  }\n\n  function initObserver() {\n    var sn = gid('sentinel'), bar = gid('progress');\n    if (!sn || !bar || !window.IntersectionObserver) return;\n    new IntersectionObserver(function (en) {\n      bar.className = en[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n    }, { threshold: 0 }).observe(sn);\n  }\n\n  function init() {\n    var sb = gid('submit'), rb = gid('retry');\n    if (!sb || !rb) return;\n    sb.addEventListener('click', showScore);\n    rb.addEventListener('click', function () { build(); window.scrollTo(0, 0); });\n    initObserver();\n    build();\n  }\n\n  function tryInit(n) {\n    if (document.getElementById('git03-cases')) {\n      init();\n    } else if (n < 40) {\n      setTimeout(function () { tryInit(n + 1); }, 50);\n    }\n  }\n\n  tryInit(0);\n\n}());\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds &middot; GIT Series Viral HepatitisGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[18,76,74,24],"tags":[],"class_list":["post-36918","post","type-post","status-publish","format-standard","hentry","category-cms","category-git","category-morning-rounds","category-neet-pg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viral Hepatitis - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viral Hepatitis - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds &middot; GIT Series Viral HepatitisGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T14:24:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T14:25:08+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Viral Hepatitis\",\"datePublished\":\"2026-06-03T14:24:06+00:00\",\"dateModified\":\"2026-06-03T14:25:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/\"},\"wordCount\":37,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"CMS\",\"GIT\",\"Morning Rounds\",\"NEET PG\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/\",\"name\":\"Viral Hepatitis - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-03T14:24:06+00:00\",\"dateModified\":\"2026-06-03T14:25:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/viral-hepatitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viral Hepatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viral Hepatitis - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/","og_locale":"en_US","og_type":"article","og_title":"Viral Hepatitis - atsixty","og_description":"Morning Rounds &middot; GIT Series Viral HepatitisGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round","og_url":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/","og_site_name":"atsixty","article_published_time":"2026-06-03T14:24:06+00:00","article_modified_time":"2026-06-03T14:25:08+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Viral Hepatitis","datePublished":"2026-06-03T14:24:06+00:00","dateModified":"2026-06-03T14:25:08+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/"},"wordCount":37,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["CMS","GIT","Morning Rounds","NEET PG"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/","url":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/","name":"Viral Hepatitis - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-03T14:24:06+00:00","dateModified":"2026-06-03T14:25:08+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/cms\/viral-hepatitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Viral Hepatitis"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=36918"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36918\/revisions"}],"predecessor-version":[{"id":36919,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36918\/revisions\/36919"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=36918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=36918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=36918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}